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OBJECTIVES The goal of this study was to assess atrial natriuretic peptide (ANP) levels during inhalation
of iloprost in severe primary (PPH) and nonprimary pulmonary hypertension (NPPH).
BACKGROUND The ANP system is activated in pulmonary hypertension and may help protect from right
ventricular (RV) decompensation. It is unknown if ANP regulation is the same in severe PPH
and NPPH and if the dynamic regulation is intact in a highly activated ANP system.
METHODS In 11 patients with PPH and seven patients with NPPH, right heart catheter investigations
were performed. Pulmonary and systemic artery ANP and cyclic guanosine monophosphate
(cGMP) levels as well as hemodynamics were measured before and after iloprost inhalation.
RESULTS The baseline hemodynamics of patients with PPH and patients with NPPH were comparable
(mean pulmonary artery pressure [mPAP]: 61 6 5 mm Hg vs. 52 6 5 mm Hg, pulmonary
vascular resistance [PVR]: 1,504 6 153 dynezszcm25 vs. 1,219 6 270 dynezszcm25. Atrial
natriuretic peptide and cGMP levels were increased about tenfold and fivefold compared
with controls in both PPH and NPPH. Iloprost inhalation significantly decreased mPAP
(29.1 6 2.5 mm Hg vs. 27.9 6 1.5 mm Hg), PVR (2453 6 103 dynezszcm25 vs. 2381 6
114 dynezszcm25), ANP (299 6 63 pg/ml vs. 2108 6 47 pg/ml) and cGMP (24.6 6
0.9 nM vs. 24.2 6 1.6 nM). Baseline ANP including all patients significantly correlated with
PVR, right atrial pressure, cardiac index, RV ejection fraction, mixed venous oxygen
saturation and cGMP.
CONCLUSIONS The ANP system is highly activated in patients with severe PPH and NPPH. Atrial
natriuretic peptide levels are significantly correlated with parameters of RV function and pre-
and afterload. Iloprost inhalation causes a rapid decrease in ANP and cGMP in parallel with
pulmonary vasodilation and hemodynamic improvement. (J Am Coll Cardiol 2001;38:
1130–6) © 2001 by the American College of Cardiology
As therapies of left heart dysfunction have been altered
based on investigations into neurohormonal profiles, there
may be potential therapies of right heart failure that may be
discovered by investigation of the neurohumoral system.
Atrial natriuretic peptide (ANP) is a potent pulmonary
vasodilator (1) and possesses considerable antiproliferative
(2–4) and diuretic properties. These features are the oppo-
site of the pathophysiologic abnormalities encountered in
primary pulmonary hypertension (PPH) and nonprimary
pulmonary hypertension (NPPH), such as pulmonary vaso-
constriction, pulmonary artery remodeling with prolifera-
tion of various cell types and edema formation. The effect of
ANP is directly antagonistic to the renin-angiotensin-
aldosterone system (5) and to endothelin, the latter of which
has been shown to be increased in pulmonary hypertension
(6). In addition, ANP has successfully been employed to
ameliorate vasoconstriction (7) and remodeling (3) in hy-
poxic pulmonary hypertension in animal models. All this is
consistent with the concept that ANP may serve as a
negative feedback mechanism in pulmonary hypertension
(7), slowing down the progression of disease. In pulmonary
hypertension due to congestive heart failure, it was demon-
strated that the ANP level is a marker of left ventricular
failure. In contrast, in patients suffering from lung diseases
like chronic obstructive pulmonary disease (COPD), inter-
stitial fibrosis and pulmonary hypertension, ANP levels
were found to be correlated with parameters of right, rather
than left, ventricular function (8,9).
Primary pulmonary hypertension is a disease of unknown
origin and poor prognosis (10,11). Previous studies have
shown increased ANP levels in patients with PPH (12,13),
but it is unknown whether the ANP system is activated to
the same extent as in NPPH. Moreover, there is a lack of
information whether the chronically activated ANP system
still dynamically responds to acute changes in pulmonary
hemodynamics. To induce such changes, we employed
iloprost, a stable analogue of prostacyclin that was admin-
istered after aerosolization via the inhalative route to min-
imize the systemic side effects of the drug (14). Previous
studies with this approach have demonstrated preferential
pulmonary, compared with systemic, vasodilation, with the
vasorelaxant response leveling off within approximately 1 h.
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The aim of this study was to characterize baseline ANP
levels and their responses to short-term iloprost inhalation
in patients with severe primary, compared with non-
primary, precapillary pulmonary hypertension.
METHODS
Patients. As depicted in Table 1, a total of 18 patients was
enrolled in the study. In 11 patients, PPH was diagnosed
based on the criteria of the National Institute of Health
registry on PPH (10), and seven patients were classified as
suffering from pulmonary hypertension with associated or
underlying chronic diseases (Table 2). The study was
approved by the local ethics committee, and each patient
gave written informed consent for catheterization and
short-term vasodilator testing. Four of the patients with
PPH were tested three times, five patients twice and two
patients once. At least 12 weeks separated repeat tests. One
of the patients with NPPH was tested three times and one
twice, with the other patients with NPPH being tested
once. All patients were admitted to our hospital for testing
of pulmonary vasoreactivity and therapy options after having
received a diagnosis of severe pulmonary hypertension. All
patients were investigated by electrocardiogram; pulmonary
function test; echocardiography; perfusion and ventilation
scintillation scan and spiral computed tomography (CT)
and/or pulmonary angiography; high resolution CT of the
lung; and laboratory screening for liver disease, chronic viral
infection, renal disease, parasitic disease and collagen vas-
cular disease. Patients were assigned to the PPH group if all
of the above investigations gave normal results and/or no
underlying or associated disease could be identified. Patients
with NPPH were eligible for the study if their mean
pulmonary arterial pressure (mPAP) was .40 mm Hg.
Exclusion criteria were congestive heart disease as suggested
by echocardiography and/or a pulmonary artery wedge
pressure (PAWP) .12 mm Hg. During the hospital stay,
the patients remained on their maintenance therapy, which
included low-dose calcium antagonists and diuretics.
Twenty-four hours before vasodilator testing, therapy with
calcium antagonists was withheld. None of the patients was
treated with beta-adrenergic blocking agent medication for
at least six weeks before inclusion.
Hemodynamic studies and inhalation procedure. A total
of 34 diagnostic right heart catheterizations were performed
using a fiberoptic thermodilution pulmonary artery catheter
(Baxter Edwards 93A, 754H, 7.5F) for measurement of
right atrial pressure (RAP), mPAP and PAWP, cardiac
output (CO), right ventricular ejection fraction (RVEF)
(15) and mixed-venous oxygen saturation (SVO2) and for
drawing blood samples. A femoral artery catheter was
employed for measuring mean systemic arterial pressure
(mSAP) and arterial oxygen saturation and for drawing
blood samples. Iloprost (Ilomedin, Schering AG, Berlin,
Germany, 100 mg/ml) was diluted 1:10 in NaCl 0.9% and
jet-nebulized with room air at a pressure of 80 kPa (fluid
flux 0.9 ml/min, mass median aerodynamic diameter of
particles 2.8 mM, geometric standard deviation 2.6 as
determined by impactor technique) and delivered to a spacer
connected to the afferent limb of a y-valve mouthpiece for
12 min (14,16–19), resulting in an inhaled dose of about
3 mg (20). Before (baseline) and immediately after aerosol-
ization of iloprost, hemodynamic measurements were per-
formed, and blood samples for blood gas analysis were
drawn.
Sample collection. Blood samples for plasma ANP and
cyclic guanosine monophosphate (cGMP) were taken from
the pulmonary and systemic artery in parallel with perfor-
mance of hemodynamic measurements. Blood was drawn
into chilled tubes containing ethylenediaminetetraacetic
Table 1. Epidemiological Data, Pulmonary Function and
Baseline Hemodynamics in PPH and NPPH
PPH NPPH 1
n, patients 11 7 2
Height, cm 166 6 2 168 6 2 NS
Weight, kg 64 6 2 63 6 3 NS
Age, yrs 42 6 3 47 6 5 NS
Gender, M/F 3/8 2/5 2
VC, % 90 6 3 79 6 10 NS
FEV1, l 2.6 6 0.2 2.0 6 0.3 NS
DLCO, % 65 6 6 26 6 5 1
PaO2, mm Hg 76 6 5 68 6 5 NS
mPAP, mm Hg 61 6 5 52 6 5 NS
CI, l/min/m2 1.9 6 0.1 2.4 6 0.4 NS
PVR, dynezszcm25 1,504 6 153 1,219 6 270 NS
mSAP, mm Hg 87 6 4 88 6 4 NS
RVEF, % 14 6 2 18 6 6 NS
SvO2, % 55 6 2 61 6 6 NS
PAWP, mm Hg 4.5 6 0.5 5.1 6 1 NS
RAP, mm Hg 7.6 6 1.8 7.1 6 2.2 NS
CI 5 cardiac index; FEV1 5 forced expiration volume in one second; mPAP 5 mean
pulmonary artery pressure; mSAP 5 mean systemic pressure; NPPH 5 nonprimary
pulmonary hypertension; PAWP 5 pulmonary artery wedge pressure; PPH 5
primary pulmonary hypertension; PVR 5 pulmonary vascular resistance; RAP 5
right atrial pressure; RVEF 5 right ventricular ejection fraction; SvO2 5 mixed
venous oxygen saturation; VC 5 vital capacity; 1 5 p , 0.05 for comparison of PPH
and NPPH.
Abbreviations and Acronyms
ANP 5 atrial natriuretic peptide
cGMP 5 cyclic guanosine monophosphate
CI 5 cardiac index
CO 5 cardiac output
COPD 5 chronic obstructive pulmonary disease
CT 5 computed tomography
eNOS 5 endothelial nitric oxide synthase
mPAP 5 mean pulmonary arterial pressure
mSAP 5 mean systemic arterial pressure
NPPH 5 nonprimary pulmonary hypertension
PAWP 5 pulmonary artery wedge pressure
PPH 5 primary pulmonary hypertension
PVR 5 pulmonary vascular resistance
RAP 5 right atrial pressure
RIA 5 radioimmunoassay
RV 5 right ventricle, right ventricular
RVEF 5 right ventricular ejection fraction
SvO2 5 mixed venous oxygen saturation
1131JACC Vol. 38, No. 4, 2001 Wiedemann et al.
October 2001:1130–6 ANP in Severe PPH and NPPH
acid and 1,000 KIU/ml aprotinin (Trasylol, Bayer AG,
Leverkusen, Germany) and placed immediately on ice.
Within 2 h, the tubes were centrifuged at 3,000 rpm for
15 min at 4°C, and plasma was transferred to polypropylene
tubes and stored at 280°C. Measurements of plasma ANP
and cGMP concentrations were done in duplicate by
radioimmunoassay (RIA) (Nichols, Bad Nauheim, Ger-
many; Coulter-Immunotech, Hamburg, Germany). All
ANP measurements in one catheter investigation were done
with one assay kit. The mean interassay variation of the
ANP RIA was about 34% and of the cGMP RIA about 5%,
as determined by repetitive measurements of control probes.
These differences were compensated by correction factors
derived from a standard probe.
Statistical methods. If there were repeated tests in indi-
viduals, means of all these tests were calculated for subse-
quent analysis. Data are presented as means 6 SEM of all
patients in the two groups. The Wilcoxon matched-pair
signed-rank test (StatXact software, Cytel Software) was
used for between-group comparison, and the Pearson cor-
relation was used for estimation of linear regression. Re-
gression analysis for baseline data (Fig. 1) was calculated
based on semilogarithmic data.
RESULTS
As depicted in Table 2, five of the patients with NPPH
suffered from pulmonary fibrosis, one from chronic pulmo-
nary embolism and one from the CREST (calcinosis,
raynaud, esophageal hypomobility, sclerodactyly and telean-
giectasia) syndrome without pulmonary fibrosis (as assessed
by HR-CT) as underlying diseases. The patients with PPH
Table 2. Underlying Disease in Nonprimary Pulmonary Hypertension
Pt.
No. Diagnosis Gender
VC
%
FEV1
%
DLCO
%
mPAP
mm Hg
PVR
dynezszcm25
d PVR
dynezszcm25
1 CREST F 78 76 31 70 2,131 972
2 CVOS 1 LF F 35 38 26 53 1,311 429
3 MCTD F 98 96 26 55 598 246
4 CREST 1 LF M 52 52 17 40 642 184
5 CLE F 98 95 54 41 458 80
6 IPF M 93 69 14 52 1,296 431
7 IPF F 101 82 10 69 2,047 489
CLE 5 chronic lung embolism; CREST 5 calcinosis, raynaud, esophageal hypomobility, sclerodactyly and teleangiectasia syndrome; CVOS 5 collagen vascular overlap
syndrome; DLCO 5 diffusion capacity for carbon monoxide; FEV1 5 forced expiratory volume in one second; IPF 5 idiopathic pulmonary fibrosis; LF 5 lung fibrosis;
MCTD 5 mixed connective tissue disease; mPAP 5 mean pulmonary arterial pressure; PVR 5 pulmonary vascular resistance; VC 5 vital capacity.
Figure 1. Correlation of atrial natriuretic peptide (ANP) with baseline hemodynamic parameters. Open circles 5 patients with PPH; closed circles 5
patients with NPPH. Atrial natriuretic peptide levels were from pulmonary artery samples. cGMP 5 pulmonary artery cyclic guanylate monophosphate
concentration; CI 5 cardiac index; mPAP 5 mean pulmonary arterial pressure; mSAP 5 mean systemic arterial pressure; PVR 5 pulmonary vascular
resistance; RAP 5 right atrial pressure; RVEF 5 right ventricular ejection fraction; SvO2 5 central venous oxygen saturation.
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and NPPH did not significantly differ with respect to their
physical and hemodynamic characteristics (Table 1). Pa-
tients with PPH showed somewhat higher pulmonary artery
pressure and pulmonary vascular resistance (PVR) as well as
slightly more severe impairment of right ventricular (RV)
function than patients with NPPH, but the differences in
these parameters were not statistically significant. Pulmo-
nary function values were in the normal range in all of the
patients with PPH, except for the lowered CO diffusion
capacity (Table 1). In NPPH, signs of moderate obstruction
and restriction were found. The statistical comparison of the
pulmonary function data between the groups, however, did
not reveal significant differences, except for the CO diffu-
sion capacity (p , 0.001), which was markedly more
reduced in the patients with NPPH than in the patients
with PPH.
Atrial natriuretic peptide levels were elevated by more
than one order of magnitude in patients with PPH and
NPPH (Table 3), compared with a range of 22 pg/ml to
64 pg/ml measured in 18 healthy volunteers in a supine
position. Moreover, consistent elevation of cGMP levels
was noted, being increased approximately fivefold above
control data (Table 3, upper normal level 5 nM for the used
test). The pulmonary artery to systemic artery difference of
ANP levels was significantly different from zero in patients
with PPH but not in patients with NPPH. No significant
transpulmonary differences were noted for cGMP. None of
the ANP and cGMP concentrations displayed any statisti-
cally significant difference when comparing patients with
PPH with patients with NPPH.
The correlations between baseline hemodynamics and
pulmonary artery ANP levels are shown in Figure 1. The
analysis included both PPH and NPPH patients because
there were no significant differences between the two groups
in baseline parameters and hemodynamic responses. Atrial
natriuretic peptide was significantly correlated with RAP
(r 5 0.76) and SvO2 (r 5 20.67) as well as PVR (r 5 0.58)
and cGMP (r 5 0.45). There was no significant correlation
between ANP levels and mPAP (r 5 0.34) and PAWP (r 5
0.12). The correlation of ANP levels with RVEF and
cardiac index (CI) showed a threshold below which the
ANP levels increased drastically. For CI, this threshold was
approximately 2 l/min/m2, and for RVEF, it was approxi-
mately 20%. Linear regression analysis resulted in r 5
20.71 and r 5 20.79 between CI and RVEF and ANP,
respectively. Cyclic GMP levels showed no significant
correlation with any of the hemodynamic parameters, except
with SvO2 (r 5 20.4) (data not shown).
Iloprost inhalation had a significant effect on hemody-
namics, ANP levels and cGMP levels in both patient
groups, as shown in Table 4. A marked pulmonary vasodi-
lation was noted, associated with a minor systemic artery
pressure drop. Right atrial pressure decreased, while CI and
RVEF increased significantly (Table 4), suggesting some
acute recompensation of the RV function. The hemody-
namic responses did not significantly differ between the
PPH and the NPPH group.
Parallel with the hemodynamic changes induced by
iloprost inhalation, the pulmonary artery ANP concentra-
tions decreased significantly in both PPH and NPPH
Table 3. Baseline ANP and cGMP Levels in PPH and NPPH
PPH NPPH 1
n, patients 11 7 2
ANP pa, pg/ml 591 6 108 700 6 201 NS
ANP sa, pg/ml 468 6 63 642 6 169 NS
ANP psd, pg/ml 122 6 50* 58 6 40 NS
cGMP pa, nM 18.5 6 2.5 23.0 6 5.9 NS
cGMP sa, nM 21.3 6 3.4 23.6 6 7.2 NS
cGMP psd, nM 22.8 6 1.4 20.7 6 1.7 NS
ANP 5 atrial natriuretic peptide; cGMP 5 cyclic guanylate monophosphate;
NPPH 5 nonprimary pulmonary hypertension; pa 5 pulmonary arterial; PPH 5
primary pulmonary hypertension; psd 5 pulmonary-systemic difference; sa 5 sys-
temic arterial.
Table 4. Effect of Iloprost Inhalation on Hemodynamics and ANP and cGMP Levels in PPH
and NPPH
PPH p Value NPPH p Value 1
n, patients 11 7 —
mPAP, mm Hg 29.1 6 2.5 *** 27.9 6 1.5 *** NS
PVR, dynezszcm25 2453 6 103 *** 2381 6 114 ** NS
CI, l/min/m2 0.43 6 0.1 *** 0.35 6 0.1 ** NS
RAP, mm Hg 21.8 6 0.6 ** 22.6 6 0.9 ** NS
SvO2, % 7.8 6 2.0 *** 7.2 6 3.7 * NS
mSAP, mm Hg 23.1 6 1.2 * 24.4 6 1.8 ** NS
RVEF, % 4.3 6 1.1 *** 3.7 6 0.7 ** NS
ANP sa, pg/ml 219 6 49 2115 6 90 NS
ANP pa, pg/ml 299 6 63 * 2108 6 47 * NS
ANP psd, pg/ml 277 6 84 27.1 6 60 NS
cGMP sa, nM 27.5 6 1.4 *** 28.0 6 4.8 * NS
cGMP pa, nM 24.6 6 0.9 *** 24.2 6 1.6 ** NS
cGMP psd, nM 22.7 6 1.2 * 21.8 6 3.3 NS
*p , 0.05, **p , 0.01, ***p , 0.001 for acute effect of iloprost inhalation; 1 5 test for difference between PPH and NPPH.
ANP 5 atrial natriuretic peptide; cGMP 5 cyclic guanylate monophosphate; CI 5 cardiac index; mPAP 5 mean pulmonary
arterial pressure; mSAP 5 mean systolic arterial pressure; NPPH 5 nonprimary pulmonary hypertension; pa 5 pulmonary arterial;
PPH 5 primary pulmonary hypertension; psd 5 pulmonary-systemic difference; PVR 5 pulmonary vascular resistance; RAP 5 right
atrial pressure; RVEF 5 right ventricular ejection fraction; sa 5 systemic arterial; SvO2 5 mixed venous oxygen saturation.
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patients, associated with a smaller and more variable de-
crease in the systemic arteries. Cyclic GMP levels decreased
in both groups in the pulmonary and systemic artery. The
transpulmonary gradient of cGMP decreased significantly
during iloprost inhalation in the patients with PPH (p ,
0.05), caused by a stronger systemic (235%) than pulmo-
nary artery (225%) cGMP decrease during iloprost inhala-
tion. In the patients with NPPH, systemic and pulmonary
cGMP changes were similar (234% vs. 218%) but did not
lead to statistically significant changes in the transpulmo-
nary gradient (p 5 0.19).
The correlations between the acute changes in hemody-
namics and the corresponding changes in ANP levels are
shown in Figure 2. The closest correlation was found with
respect to changes in RAP (r 5 0.73) and CI (r 5 20.73).
There was also a significant correlation of ANP changes
with the changes in PVR (r 5 0.61), SvO2 (r 5 20.61), and
mPAP (r 5 0.51), although in PVR and mPAP this could
also be due to leverage points. There was no significant
correlation with the changes in mSAP (r 5 0.21) and
cGMP (r 5 0.23). The correlation between changes in
hemodynamics and changes in cGMP was not significant
(data not shown).
DISCUSSION
It is generally assumed that the ANP secretion depends
mainly on the transmural stretch of the left and right atrium
(21). In heart failure, however, the ventricles are also known
to be a major source of ANP production (22). In experi-
mental pulmonary hypertension, stimuli such as hypoxia,
sympathetic nerve activity and RV hypertrophy were noted
to be further strong triggers for ANP secretion (23).
Concerning the signal transduction pathways involved in
the release reaction of stretched cardiac myocytes, endothe-
lin, angiotensin II and nitric oxide are believed to be
important mediators (24). Thus, several mechanisms in-
volved in the pathophysiology of pulmonary hypertension
may contribute to severely increased circulating ANP levels.
Increased baseline ANP levels. In line with this back-
ground in this study, patients with PPH and NPPH
revealed considerably elevated ANP levels in both mixed
venous and arterial blood samples, with maximum values
surpassing 2,000 pg/ml. None of the patients was in the
normal range for ANP (,65 pg/ml), and the mean values of
PPH and NPPH patients were increased about tenfold
compared with the upper normal value. These results agree
with data of Morice et al. (13). No significant difference was
noted between PPH and NPPH patients, and analysis of
the single data showed broad overlapping of the two groups.
This suggests that the ANP system is activated in response
to the hemodynamic impairment in severe pulmonary hy-
pertension irrespective of the underlying disease.
Baseline hemodynamic parameters were significantly cor-
related with the pulmonary artery ANP levels (Fig. 1),
corresponding to previous studies (12,25). One patient with
PPH, who showed near normal ANP levels despite consid-
erably elevated PVR and mPAP, presented with a RAP of
zero due to high-dose diuretic therapy. This might explain
the large deviation from the other patients concerning the
relationship between ANP and hemodynamics. Compared
Figure 2. Correlation of atrial natriuretic peptide (ANP) changes with the hemodynamic changes in response to iloprost inhalation. Open circles 5
patients with PPH; closed circles 5 patients with NPPH. Atrial natriuretic peptide levels were from pulmonary artery samples. Abbreviations as in
Figure 1.
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with other hemodynamic parameters, mPAP was not sig-
nificantly correlated with ANP. This is in contrast to data
on patients with COPD (8) and mild pulmonary hyperten-
sion (mean PVR approximately 300 dynezszcm25) and a
slightly reduced RV function, whereas our population con-
sisted of patients with severe pulmonary hypertension,
characterized by a mean PVR of approximately 1,350
dynezszcm25 and a severely compromised RV function. This
condition results in a plateauing or even a decrease in
pulmonary artery pressure upon increasing severity of dis-
ease and may explain the poor correlation between ANP
and PAP values in our study.
Apparently, there was a “threshold” for CI and RVEF,
below which ANP levels increased dramatically (Fig. 1).
This threshold was in the range of a CI of 2 l/min/m2 and
an RVEF of 20%. This is consistent with the concept that
additional control mechanisms for ANP are activated when
overt RV decompensation occurs.
Transpulmonary ANP gradient. In the PPH group, the
pulmonary arterial ANP level was significantly higher than
the systemic arterial level (approximately 20% difference),
while such transpulmonary difference was less prominent in
NPPH (approximately 10% difference). In accord with
previous studies (26), we suggest that a changed pulmonary
ANP clearance rate may contribute to the highly elevated
circulating ANP levels in severe pulmonary hypertension.
Circulating cGMP. The circulating cGMP values in the
blood of the PPH and NPPH patients were considerably
increased compared with controls. This is in line with data
of Bogdan et al. (27). No significant difference was noted
between patients with PPH and patients with NPPH. This
finding and the presence of very high ANP levels in both
groups supports the notion that this peptide may represent
the predominant activator of guanylate cyclase(s) in patients
with pulmonary hypertension. In agreement, Muramatsu et
al. (28) demonstrated that augmented circulating cGMP
levels in experimental pulmonary hypertension are not
predominantly caused by NO but are largely attributable to
ANP. The current cGMP data show significant correlation
(r 5 0.45) between the baseline values of cGMP and ANP,
although the scattering of data also indicates that additional
factors may contribute to the elevated cGMP levels. This
could be due to increased nonpulmonary nitric oxide syn-
thases or to pulmonary sources of endothelial nitric oxide
synthase (eNOS) or other NOS isoforms, although the
pulmonary eNOS was reported to be reduced in patients
with PPH (29). Other circulating activators of the guanylate
cyclase, such as brain natriuretic peptide, may add to the
appearance of cGMP, and in addition, this is influenced by
phosphodiesterase activity. Finally, it remains unclear if the
hemodynamic alterations in the patients with PPH and
NPPH affect the cellular escape of this intracellular medi-
ator. Thus, any interpretation of the plasma cGMP data is
much more uncertain than that of the plasma ANP levels.
Dynamic control of ANP and cGMP levels. Iloprost
inhalation caused an immediate preferential pulmonary
vasodilation in both PPH and NPPH patients, with all
hemodynamic effects leveling off within approximately 1 h
(14,16–19). During aerosolization, PVR decreased by ap-
proximately 30%, and PAP by approximately 20% (Table
4). Concomitantly, ANP levels in the pulmonary artery
decreased by 19% in patients with PPH and 15% in patients
with NPPH, with values being significantly different from
pre-inhalation data for both groups. In contrast, during
intravenous prostacyclin infusion, pulmonary artery ANP
levels did not change, despite a significant hemodynamic
improvement (13). This discrepancy may be explained by
the lower basal ANP levels in that study (mean values
approximately 350 pg/ml) or by the different hemodynamic
profile of intravenous prostacyclin in comparison with
inhaled iloprost, with a more systemic than pulmonary
pressure decrease occurring in response to prostanoid infu-
sion (14).
The correlation of ANP changes with hemodynamic
changes (Fig. 2) scarcely showed any differences compared
with the baseline correlations (Fig. 1). The best correlations
were found between ANP and parameters of RV preload
and function (RAP and CI). This might suggest that the
dynamic control of the ANP secretion is dependent on right
atrial and ventricular conditions.
Cyclic GMP levels in the pulmonary artery decreased by
30% during iloprost inhalation in PPH and NPPH patients.
This might be explained by the decreasing ANP levels;
however, there was no significant correlation between the
changes in cGMP levels and ANP levels. As discussed
above, the plasma appearance of cGMP is influenced by a
large number of variables, many of which may be altered by
iloprost inhalation. This renders any interpretation of the
rapid cGMP decline in response to the prostanoid aerosol-
ization uncertain.
Conclusions. We conclude that the ANP (and the cGMP)
system is, to the same extent, massively activated in severe
PPH and NPPH. Baseline ANP levels are significantly
correlated with parameters of RV function as well as pre-
and afterload. As a rapid decline of ANP occurs in parallel
with hemodynamic improvement in response to iloprost
inhalation in PPH and NPPH, it seems that the regulation
of the ANP secretion is intact even in states of strong,
long-term stimulation. Therefore, ANP levels may be con-
sidered as a non-invasive marker of RV failure. Further
investigations into the neurohumoral system in right heart
failure are needed.
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